Company intelligence / Profile preview
Laekna
Shanghai, Shanghai, Chinalaekna.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Laekna is a clinical-stage biotech company founded in China in December 2016. It develops novel targeted therapies for oncology, liver fibrosis, and metabolic diseases. Its lead assets are LAE002 (an ATP competitive AKT inhibitor for ovarian/prostate/breast cancers and drug-resistant solid tumors) and LAE001 (an androgen synthesis inhibitor for prostate cancer). As of the end of December 2024, it has six clinical trials ongoing—including three multi-regional trials—with at least one pivotal trial underway.[1][2][3] Preclinical data show promising effects on lean mass/fat mass with their metabolic disease candidates.[2]
- Therapeutic areas
- GastroenterologyOncologyMetabolic Disorders
- Modalities
- Small moleculesCombination therapies
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
Beyond the preview
Go deeper on Laekna.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laekna.